LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers
Ovarian and endometrial cancers rank among the most common and deadliest cancers affecting women globally. One of the most important factors that impacts patient survival is how early the tumor is detected. Unfortunately, these cancers often present vague symptoms that usually don't show up until the disease is already in an advanced stage. This makes early diagnosis and screening quite difficult. As a result, researchers are actively seeking better diagnostic tools and treatment approaches. In recent years, non-coding RNAs (ncRNAs) have gained significant attention for their key roles in controlling various cellular activities, especially in cancer. Among them, long non-coding RNAs (lncRNAs) are being explored for their potential as therapeutic targets, as well as their usefulness as diagnostic markers and indicators of poor outcomes. This article focuses on how lncRNAs could be crucial in driving or suppressing cell growth, invasion, metastasis, cell death, and resistance to drugs in ovarian and endometrial cancers.